SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors scrutinize the company's aggressive increase in AI-related capital expenditure and its impact on near-term margins. Despite delivering robust revenue growth and beating earnings expectations, the market is reacting cautiously to the open-ended spending plans, with community debate split between those seeing a long-term AI buying opportunity and those concerned about the company's valuation and capital allocation.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as investors closely watch its earnings performance to gauge the sustainability of the AI infrastructure boom, with the community focused on the company's ability to monetize its massive cloud and AI investments. Market participants are debating how the stock's capital expenditure strategy and growth metrics compare against other mega-cap tech giants amid a volatile period for the sector.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors focus on its pivot into AI and cloud infrastructure through the Northern Data acquisition, fueled by significant support from Tether. The community is actively discussing a potential short squeeze, citing high short interest, elevated borrowing costs, and strong insider alignment with the current political administration.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

Investors are actively debating UAMY's role in Western technological sovereignty as the stock benefits from a broader rotation into critical minerals and rare earth plays tied to AI infrastructure and national defense. The community remains hyper-focused on supply chain scarcity and potential institutional accumulation while navigating the persistent volatility and intense short-selling activity typical of this sector.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure despite reporting strong quarterly earnings, as investors express skepticism over the company's aggressive, multi-billion dollar capital expenditure plans for AI infrastructure. The community remains deeply divided, with some investors viewing the stock as a prime dip-buying opportunity given its dominant market position, while others are concerned that rising costs and margin compression are unsustainable.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing significant momentum after the FDA granted priority review to the sNDA for AXS-05 to treat Alzheimer's disease agitation, with a decision expected by April 30, 2026. The community is actively discussing the stock's strong commercial execution, potential for international partnerships, and bullish sentiment following upward analyst price target revisions.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is seeing massive institutional interest driven by strong cloud revenue growth and a high-conviction AI strategy that positions it as a leader in full-stack integration. Investors are actively discussing the company's ability to maintain search dominance while simultaneously scaling its AI infrastructure, with sentiment shifting toward a long-term bullish outlook as analysts consistently revise price targets upward.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit Inc. is trending as investors debate its valuation and growth potential ahead of an upcoming earnings report, with sentiment split between optimism over its ad revenue and concerns regarding slowing user growth. The discussion is heavily centered on technical setups, with traders closely watching for potential breakouts or volatility-driven sell-offs as the company navigates a competitive social media landscape.

Huachen AI Parking Management Technology Holding Co., Ltd. engages in the provision of smart parking solutions and equipment structural parts. Its products include structural parts, garage structural parts, materials such as customized steel and load bearing steel plates for cubic parking equipment, and railroad accessories. The company was founded by Lu Bin on September 30, 2021 and is headquartered in Jiaxing, China.

Huachen AI Parking Management Technology Holding Co. Ltd. - Ordinary Shares - Class A

Huachen AI Parking Management Technology Holding Ord Shs

HCAI is trending as a low-float, speculative Chinese small-cap stock that community members are actively monitoring for potential short-squeeze activity following a recent reverse stock split. While some traders view the symbol as an opportunity for quick momentum gains, others are warning of a typical pump-and-dump cycle, pointing to limited company transparency and aggressive price volatility.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is seeing increased investor activity and community interest following the start of R2 production and the company's efforts to maintain operational timelines despite recent weather challenges. Discussions are heavily focused on the stock's potential for an earnings-driven breakout, with participants closely debating the company's path to profitability and the impact of the upcoming R2 vehicle launch.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The outcome was unsurprising as Novo Nordisk Foundation controls 77% of the votes at the Novo Nordisk Annual General Meeting.</li><li>Sorensen said he intends to stay on in the role for a maximum of three years.</li></ul>Novo Nordisk (NVO) said on Friday that Lars Rebien Sørensen, the chair of its dominant shareholder, Novo Nordisk Foundation, has been elected as chair of the Board at the drugmaker, replacing Helge Lund.The outcome was unsurprising as Novo Nordisk Foundation controls 77% of votes at the Novo Nordisk Annual General Meeting through its investment company, Novo Holdings A/S. Sørensen was also previously the CEO of Novo from 2000 to 2016. &nbsp;<h2 class="st-heading-2">The New Chairman</h2>Sørensen, however, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916459">said</a> that he intends to hold the position only for a period of two to three years. “My mandate is very clear. I have two important tasks together with the Board: First, to support the CEO and the management in its transformation plans to regain its competitive leadership, and second, prepare the way for my successor,” he said.Novo named Mike Doustdar as CEO of the company in August after Lars Fruergaard Jørgensen stepped down in May. Jørgensen decided to step down as per a mutual agreement with the Novo Nordisk board. The board stated that the change is being made in light of Novo Nordisk's recent market challenges, the company’s declining share price since mid-2024, and discussions with the Novo Nordisk Foundation.Sorensen on Friday also said that he is looking to “strengthen the board with some qualifications,” with recent pharma or over-the-counter business experience. “We might see a future where our GLP-1 product is going in this direction,” he said, highlighting the company’s ambitions to make its drugs over-the-counter without prescription.Minority shareholders, including Norway’s sovereign wealth fund and CalSTRS, opposed Sorensen’s appointment. Proxy advisor ISS also urged investors to abstain, citing “limited transparency and accountability to minority shareholders.”<h2 class="st-heading-2">Other appointments</h2>Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday.The new appointment comes amid Novo’s intense competition in the weight-loss drug market with its U.S. counterpart, Eli Lilly, and a dramatic board rupture last month, in which disagreements over governance principles between Novo’s board and the foundation prompted more than half of the supervisory board to resign.<a href="https://stocktwits.com/symbol/NVO">Shares of NVO</a> traded 2% lower by Thursday noon. On Stocktwits, retail sentiment around NVO rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.A Stocktwits user expressed optimism about the stock, citing the price-to-earnings valuation.<stembedurl>https://stocktwits.com/Bassfisher89/message/636229521</stembedurl>Another expressed hopes for the stock’s prospects.<stembedurl>https://stocktwits.com/Natetruu/message/636213210</stembedurl>NVO shares are down by 44% this year and by 54% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/scholar-rock-eyes-reapplication-for-approval-of-muscle-atrophy-therapy-in-2026/cLPQ17HRE4q">Why Did Scholar Rock Soar 26% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Brings Back Former CEO To Lead Board

Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday. 

Equity

Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday. 


The U.S. Food and Drug Administration has sent a letter to Novo Nordisk (NVO) CEO Maziar Mike Doustdar regarding the company’s promotional communication featuring Oprah Winfrey, alleging that the video is false or misleading.The video originally appeared on ABC as a Primetime Oprah Special on March 18, 2024. It also subsequently appeared on Hulu. The video is a 42-minute special program hosted by Oprah Winfrey, featuring patient testimonials from individuals who struggle with obesity and excessive weight, including those who have used Novo’s Wegovy, Ozempic, or Victoza.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-716495-09092025">alleged</a> in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. The video was also not submitted at the time of initial dissemination or publication as required by law, the agency said.“These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the safety of Wegovy, Ozempic, and Victoza, which are drugs with multiple serious, potentially life-threatening risks,” the agency said.The FDA also noted that obesity and type 2 diabetes are significant public health concerns in the U.S., and consumers who seek medical treatment for these conditions should receive truthful and nonmisleading information regarding the serious risks associated with the use of the drugs. While Novo’s Wegovy is used for weight management, its Ozempic and Victoza are used to treat type 2 diabetes.The FDA said that several advisory comments dated as long back as 2010 addressed draft promotional communications for Victoza with certain similarities to the aforementioned video. The agency expressed concerns that <a href="https://stocktwits.com/symbol/NVO">Novo</a> is promoting the three drugs in a manner that fails to present the serious risks of these drug products in a truthful and nonmisleading manner, despite the FDA’s prior comments.While the video includes numerous representations of the benefits of Wegovy, Ozempic, and Victoza made by representatives of Novo Nordisk, it omits important risk information or minimizes the risks associated with these drug products, the FDA said. Only four minutes in total were devoted to the important risks associated with GLP-1 drugs, such as Wegovy, the FDA said.The video also omits reference to how the drugs are contraindicated in patients with a personal or family history of Medullary Thyroid Cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2, it added. The omissions are exacerbated by statements from Amanda Velazquez, a paid consultant of Novo, made on the video, the FDA said.NVO stock is down by 33% this year and by 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-tumbles-7-percent-after-fda-letter/chwyNFWRdzV">Hims &amp; Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’ 

The FDA alleged in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. 

Novo Nordisk (NVO) announced on Tuesday that its new obesity treatment, Cagrilintide, reduced body weight by 11.8% after 68 weeks in a late-stage study.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916427">reported</a> an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in the trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy, plus lifestyle intervention, for adults with obesity or overweight and a weight-related comorbidity without diabetes. The above levels of weight reduction were observed in participants who adhered to the treatment. Regardless of adherence, average weight loss with Cagrilintide was 11.5% compared to 3.0% with placebo after 68 weeks.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:575/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_9_59_21_AM_png_2efadb4b5b.webp" alt="NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="575" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment that the stock rallied only 2-3% on good news.<stembedurl>https://stocktwits.com/King990/message/628811943</stembedurl>Cagrilintide works differently from currently approved GLP-1-based treatments for weight loss, including Novo’s Wegovy and Eli Lilly’s Zepbound. The new drug mimics the naturally occurring hormone amylin that helps control blood glucose levels and appetite by slowing gastric emptying, reducing glucagon secretion, and promoting satiety.The company also stated that approximately one in three participants receiving Cagrilintide achieved 15% or more weight loss, compared to approximately one in 20 participants receiving a placebo, when patients adhered to the treatment.Novo stated that the drug was well-tolerated, while adding that the most common side effects were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation. These side effects were mainly temporary and mild to moderate, and 1% of participants discontinued the study due to nausea, compared to 0.1% of participants who received a placebo.“We’re excited that these data, the first phase 3 data of a next-generation amylin therapy, show promise, and we look forward to further investigating cagrilintide’s potential in the dedicated phase 3 RENEW programme,” said Martin Holst Lange, chief scientific officer and executive vice president of Research and Development at Novo Nordisk.Another late-stage programme investigating the efficacy and safety of Cagrilintide in people with obesity or overweight is due to start in the fourth quarter of this year.Separately, Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://bloomberg.com/news/articles/2025-09-16/novo-plans-to-seek-us-approval-for-its-high-dose-obesity-shot?sref&amp;#61;8QBk7toa">reported</a> on Tuesday that Novo plans to seek U.S. regulatory approval for a high-dose version of Wegovy. Though the drugmaker hasn’t yet formally announced its U.S. plans, it intends to file for the U.S. Food and Drug Administration approval, said Lange at the European Association for the Study of Diabetes conference in Vienna, according to the report.NVO stock is down 34% this year and by about 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-opens-probe-into-174000-plus-tesla-model-y-vehicles/chwyiNgRdz5">US Regulator Opens Probe Into 174,000-Plus Tesla Model Y Vehicles – Check Out Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-Stage Study

The company reported an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in a trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy. 

Danish drugmaker Novo Nordisk (NVO) has entered into a multi-year research collaboration with Replicate BioScience to develop new therapeutic candidates, the privately held clinical stage company stated on Thursday.The collaboration will bring together Novo’s therapeutic knowledge and drug development expertise with Replicate’s novel srRNA platform to develop new therapeutic candidates to treat obesity, type 2 diabetes, and other cardiometabolic diseases, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://replicatebioscience.com/replicate-bioscience-announces-partnership-with-novo-nordisk-to-unlock-self-replicating-rna-therapies-for-obesity-and-diabetes/">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> trended within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels. According to Stocktwits data, retail chatter about the stock increased by about 157% over the past 30 days. Shares of the company traded 1% lower at the time of writing.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_10_55_20_AM_png_5dd1ac88ba.webp" alt="NVO's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they have purchased more shares of the company.<stembedurl>https://stocktwits.com/bginvest/message/626846711</stembedurl>Under the new deal, Novo Nordisk will receive a defined, exclusive, and worldwide license to use Replicate’s self-replicating RNA platform for the development and commercialization of treatments. Meanwhile, Replicate will receive research funding and is eligible to receive up to $550 million from Novo, including an up-front cash payment and potential milestone payments. Replicate is also eligible to receive tiered royalties on future product sales as part of the deal.Last month, Novo, which is battling competition from its U.S. rival Eli Lilly, lowered its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and diabetes drug Ozempic for the second half of the year.The firm now expects sales growth of 8% to 14% during the year at a constant exchange rate, down from its previous estimate of 13% to 21%. Operating profit growth is now expected to be 10% to 16%, down from its prior outlook of 16% to 24%.Last week, it was reported that the drugmaker has implemented a hiring freeze, which will apply across all markets and departments, with an exemption for business-critical roles. Former CEO of Novo Nordisk, Lars Fruergaard Jørgensen, had earlier stated that the company is taking measures to sharpen its commercial execution and ensure efficiencies in cost base while continuing to invest in future growth.NVO stock is down 35% this year and approximately 59% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/teva-pharma-announces-fda-approval-for-generic-weight-loss-medication/chs6ffWRdmt">This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today?

Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop and commercialize treatments.

Danish drugmaker Novo Nordisk (NVO) has implemented a hiring freeze, which will apply across all markets and departments, Bloomberg reported on Wednesday, citing a company spokesperson.Business-critical roles, however, would be exempted from the hiring freeze, the report <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-20/novo-nordisk-s-new-ceo-starts-hiring-freeze-in-cost-cutting-push-mejscm29">said</a>. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">Novo</a> remained within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:564/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_7_07_43_AM_png_be5874fe43.webp" alt="NVO's Sentiment Meter and Message Volume as of 7:08 a.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="564" height="62"><figcaption>NVO's Sentiment Meter and Message Volume as of 7:08 a.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to trade over $100 in a year.<stembedurl>https://stocktwits.com/Eesnimi/message/625897097</stembedurl>Another user opined that the stock can rally up to $70 if it can break the $55 mark.<stembedurl>https://stocktwits.com/trading_momentum/message/625893966</stembedurl>Former CEO, Lars Fruergaard Jørgensen, said earlier this month that the company is taking measures to sharpen its commercial execution further, and ensure efficiencies in cost base while continuing to invest in future growth. Novo’s new CEO, Maziar Mike Doustdar, took charge on August 7.Last month, the company, battling competition from its U.S. rival Eli Lilly, <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-slashes-full-year-guidance/cho9UwAR5yE">lowered</a> its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and diabetes drug Ozempic for the second half of the year.The firm now expects sales growth of 8% to 14% during the year at a constant exchange rate, down from its previous estimate of 13% to 21%. Operating profit growth is now expected to be 10% to 16%, down from its prior outlook of 16% to 24%.The company now sees lower growth for Wegovy in the U.S. obesity market and for Ozempic in the U.S. diabetes market, as well as lower-than-expected penetration for Wegovy in select international operations markets.Novo’s <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/careers/find-a-job/career-search-results.html?searchText=&amp;countries=&amp;categories=">website</a> currently shows multiple job openings in the U.S. and mainland China, but merely eight open positions in Denmark. According to the company, it employs over 77,000 people in 80 offices around the world.NVO stock is down by 36% this year and by about 60% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ioc-bpcl-reportedly-resume-russian-crude-purchase-as-discounts-widen/chsiZrQRdh3">IOC, BPCL Reportedly Resume Russian Crude Purchase As Discounts Widen</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year

Novo’s website currently shows multiple job openings in the U.S. and mainland China, but merely eight open positions in Denmark.

Danish drugmaker Novo Nordisk (NVO) on Tuesday said that its blockbuster drug Ozempic is now approved in Canada to reduce the risk of kidney function decline, end-stage kidney disease, and cardiovascular death in patients with type 2 diabetes and chronic kidney disease (CKD).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO</a> trended within the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels. According to data from Stocktwits, retail chatter around the stock jumped 67% over the past 24 hours and by about 197% over the past seven days as of early hours on Tuesday. &nbsp;<figure class="image"><img style="aspect-ratio:626/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_1_02_48_PM_png_e2a2c52a54.webp" alt="NVO's Sentiment Meter and Message Volume as of 1:03 p.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="626" height="62"><figcaption>NVO's Sentiment Meter and Message Volume as of 1:03 p.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user said that they do not see much downside for the stock.<stembedurl>https://stocktwits.com/bullish51892/message/625797538</stembedurl>The approval from Health Canada for the indications is based on the results of a trial in which Semaglutide 1 mg demonstrated a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared to placebo. Semaglutide is the active ingredient in Ozempic.The trial was initiated in 2019 and was stopped early due to efficacy, based on a recommendation from an Independent Data Monitoring Committee, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.ca/content/dam/nncorp/ca/en/press-releases/ozempic-ckd-indication-press-release-english-aug192025.pdf">said</a>.Ozempic is already indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control. It was approved by Health Canada in 2018.CKD and type 2 diabetes are interconnected. Around 40% people with type 2 diabetes develop the disease. CKD is defined as the presence of kidney damage, or a decreased level of kidney function, for a period of three months or more. It is estimated to impact nearly four million Canadians.Novo is currently attempting to increase the use cases for its GLP-1 category drugs, including Ozempic and the weight-loss drug Wegovy. Last week, the company said that the U.S. Food and Drug Administration has also approved Wegovy for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. MASH is a serious liver disease characterized by fat accumulation, inflammation, and liver cell damage.NVO stock is down by 37% this year and by about 60% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ptc-therapeutics-stock-in-limelight-after-fda-refuses-approval-for-drug-to-treat-neurodegenerative-disease/chsgFLxRdW5">PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Health Canada Approves Novo’s Ozempic to Reduce Risk Of Kidney Function Decline, Cardiovascular Death

The approval from Health Canada for the indications is based on the results of a trial in which Semaglutide 1 mg demonstrated a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared to placebo. 

NDVG
NuShares ETF Trust - Nuveen Dividend Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest NDVG News

NDVGNuShares ETF Trust - Nuveen Dividend Growth ETF